Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Gemcitabine + G-CSF in Recurrent Uterine Leiomyosarcoma
NCT00031629Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Jan 2005
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in uterine leiomyosarcoma (uLMS), sponsored by GOG Foundation. Primary endpoints: Frequency and duration of objective response up to 5 years and Frequency of severity of observed adverse effects up to 5 years. Started Jan 2005; status: completed.
02
Drugs
docetaxelgemcitabine
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT00031629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031629.